FLAGSTAFF, Ariz. & COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) and Spectranetics (NASDAQ: SPNC) today announced the enrollment of the first two patients in the VIVA II: SALVAGE Trial. The patients were treated by Dr. Eric Dippel at Midwest Cardiovascular Research in Davenport, Iowa. The physician-sponsored SALVAGE Trial, is designed to evaluate the safety and performance of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface and the Spectranetics TURBO-Booster® and TURBO elite® laser catheter with the CVX-300® Excimer Laser System for the treatment of peripheral vascular disease (PVD) in the superficial femoral artery (SFA). Specifically, the study will evaluate the effectiveness of this combination therapy as a treatment for patients with chronic lower-limb ischemia associated with femoro-popliteal in-stent restenosis.
